Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells

Copyright © 2010 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 138(2011), 1 vom: 24. Jan., Seite 85-96
1. Verfasser: Khan, Sameena (VerfasserIn)
Weitere Verfasser: Burt, Deborah J, Ralph, Christy, Thistlethwaite, Fiona C, Hawkins, Robert E, Elkord, Eyad
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2011
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Carcinoembryonic Antigen FOXP3 protein, human Forkhead Transcription Factors IL2RA protein, human Interleukin-2 Interleukin-2 Receptor alpha Subunit mehr... Membrane Glycoproteins trophoblastic glycoprotein 5T4, human Interferon-gamma 82115-62-6 tremelimumab QEN1X95CIX